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Abstract
Background: Although highly active antiretroviral therapy (HAART) reduces mortality in the
developed world, it remains undocumented in resource-poor settings. We assessed the effect of
HAART on patient mortality and tuberculosis incidence rate under routine clinical care conditions
in Ethiopia. The objective of this study was to assess the effect of HAART on patient mortality and
tuberculosis incidence rate under routine clinical care conditions in a resource-limited setting in
south Ethiopia. Starting in January 2003, we followed all consecutive adult HIV infected patients
who visited the HIV clinic. Since August 2003, we treated patients with HAART. Only basic
laboratory services were available.
Results: We followed 185 patients in the pre-HAART cohort and 180 patients in the HAART
cohort. The mortality rate was 15.4 per 100 person-years of observation (PYO) in the HAART
group and tuberculosis incidence rate was 3.7 per 100 PYO. In the pre-HAART group, the
mortality rate was 58.1 per 100 PYO and the tuberculosis incidence rate was 11.1 per 100 PYO.
HAART resulted in a 65% decline in mortality (adjusted hazard ratio [95%CI] = 0.35 [0.19–0.63];
P < 0.001). Tuberculosis incidence rate was lower in the HAART group (adjusted hazard ratio
[95%CI] = 0.11 [0.03–0.48]; P < 0.01). Most of the deaths occurred during the first three months
of treatment.
Conclusion: HAART improved survival and decreased tuberculosis incidence to a level similar to
that achieved in the developed countries during the early years of HAART. However, both the
mortality and the tuberculosis incidence rate were much higher in terms of absolute figures in this
resource-limited setting. Attention should be paid to the early weeks of treatment when mortality
is high. The high tuberculosis incidence rate, when coupled with the improved survival, may lead to
increased tuberculosis transmission. This highlights the need for strengthening tuberculosis
prevention efforts with the scale-up of treatment programmes
Background
The survival benefit of highly active antiretroviral therapy
(HAART) in HIV infection and its impact on the incidence
of opportunistic infections have been well studied in the
developed world [1-3]. In resource-poor settings, where
such treatment was started only recently, limited data exist
both on treatment results and on how to carry out such
interventions [4-6]. As a result, the existing treatment
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guidelines and recommendations are based on data from
the developed world [7].
As HAART is effective in treating HIV infected patients,
conducting randomized, placebo-controlled trials is
unethical. Thus, the next-best method of measuring the
effectiveness of HAART on disease progression in new set-
tings is cohort studies. In this study, we present data from
two cohorts of treatment-naïve patients in south Ethiopia.
The objective of this study was to assess the effect of
HAART on patient mortality and tuberculosis incidence
rate under routine clinical care conditions in a resource-
limited setting in south Ethiopia.
Results
Baseline characteristics
We enrolled and followed 185 patients (90 men and 95
women) in the pre-HAART cohort and 180 (102 men and
78 women) in the HAART cohort. 85 patients contributed
person-time for both cohorts. At baseline, the two groups
were similar for age, sex, BMI or TLC categories. However,
patients receiving HAART had more advanced disease. The
follow-up period was longer in the HAART group [50
weeks (IQR, 21–68) vs. 19 weeks (IQR, 10–34). Table 1
compares the baseline characteristics of the two groups.
The HAART cohort
Patient follow-up
At the end of the study, 136 patients (76%) were under
regular follow-up, 25 (13.9%) died, 9 (5%) stopped treat-
ment, 5 (2.8%) were lost to follow-up and 5 patients
(2.8%) were transferred to other health institutions. 13
out of the 25 deaths (52%) occurred at home, 11(44%) at
the hospital, and in one patient place of death was not
recorded. The reasons for stopping treatment were: drug
related side effects (3 patients), lack of public transport to
the hospital (1 patient), afraid of swallowing tablets in
front of her husband (1 patient), two patients preferred
taking traditional medicine ("holy water") instead of
drugs, and no reason was given for two patients.
Antiretroviral drugs prescribed
93 patients (52%) used the first line treatment drugs
(d4T/3TC/NVP) and 48 patients (27%) received d4T/
3TC/EFV. Twenty-five patients (14%) got ZDV/3TC/NVP
while the remaining 14 patients (8%) received ZDV/3TC/
EFV. 10 patients (6%) had previous exposure to antiretro-
viral drugs. Of these, 8 had received triple drugs and two
dual therapy. Their inclusion in the analysis did not affect
the results. Twenty-six patients were on concomitant
antituberculosis treatment, including 8 in their intensive
phase of treatment.
Mortality rate
25 patients (14%) died during the follow-up. The mortal-
ity rate was 15.4 per 100 PYO (25 deaths per 162.2 PYO).
After starting treatment, the median time to death was 9
weeks (IQR, 4–25). None of the patients with stage II dis-
ease died. Over half of the deaths (13/25, 52%) occurred
in patients with stage IV disease.
Tuberculosis incidence rate
Six patients (5 men and 1 woman) developed tuberculosis
during the treatment period. The median time to the diag-
nosis of tuberculosis was 32 weeks (IQR, 14–56). Two of
the patients had smear positive pulmonary tuberculosis
(PTB+), two patients had smear negative pulmonary
tuberculosis (PTB-) and two patients had extra pulmonary
tuberculosis (EPTB). The incidence rate of tuberculosis
was 3.7 per 100 PYO (6 cases per 162.2 PYO).
Drug side effects
We observed 124 episodes of drug related side effects.
Peripheral neuropathy was the most common side effect
(48 of 124 patients, 38.7%) followed by skin rash (41/
124, 33.1%) and anaemia (11/124, 8.9%). Two men tak-
ing an EFV containing regimen developed breast enlarge-
ment. One patient, taking a d4T-containing regimen, died
of pancreatitis (diagnosed clinically). Anaemia was the
earliest side effect recognized, occurring at a median time
of 4.4 weeks (IQR, 4.4–16.6) followed by skin rash
(median, 4.6 weeks; IQR, 3.6–13.0). Two patients with
anaemia needed blood transfusion. Table 2 summarizes
the side effects.
The pre-HAART follow-up
At the end of the pre-HAART period, 10 patients (5.4%)
were lost to follow-up, 8 (4.3%) were transferred to
another health institution, 47 (25.4%) died and 120
(64.9%) patients were under regular follow-up. 38 out of
the 47 deaths (81%) occurred at home, 8 (17%) at the




Mean age in years (SD) 33 (8.9) 34 (9.0)
Gender; count (%)
Male 90 (49) 102 (57)
Female 95 (51) 78 (43)
WHO stage; count (%)
II 28 (15) 15 (8)
III 132 (71) 120 (67)
IV 25 (14) 45 (25)
Median TLC/ml (range) 1200 (200–380) 1140 (200–4800)
Mean Hgb (SD) 8.6 (2.2) 9.2 (1.9)
Oral thrush; count (%) 67 (36) 50 (28)
TLC=Total lymphocyte count; Hgb=Haemoglobin in gram per 
decilitre; SD=Standard deviationAIDS Research and Therapy 2006, 3:10 http://www.aidsrestherapy.com/content/3/1/10
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hospital and for one patient place of death was not
recorded. The pre-HAART mortality rate was 58.1 per 100
PYO (47 deaths per 80.9 PYO) and the tuberculosis inci-
dence rate was 11.1 per 100 PYO (9 cases per 80.9 PYO).
The pre-HAART vs. HAART cohorts: comparison of 
mortality and tuberculosis incidence
HAART resulted in a decrease of mortality (adjusted HR
[95%CI] = 0.35 (0.19–0.63) P < 0.001). Figure 1 shows
the Kaplan-Meier survival curves. Using Cox-regression
analysis adjusting for oral thrush, diarrhea, total lym-
phocyte count, anaemia and low body mass index shows
improved survival for patients receiving HAART (Figure
2). Tuberculosis incidence rate was also lower in the
HAART group (adjusted HR [95%CI] = 0.11 [0.03–0.48];
P < 0.01). Figure 3 shows Kaplan Meier survival plots for
tuberculosis occurrence.
Other factors predicting higher mortality rates among our
patients were oral thrush, TLC <1200/ml, BMI less than
18.5 kg/m2, anaemia, WHO clinical stages III or IV and
presence of prolonged diarrhea at baseline. However,
when stratified by treatment group, only low TLC and low
BMI were associated with increased mortality both in the
pre-HAART (BMI, P = 0.016; TLC, P= 0.009) and in the
HAART groups (BMI, P = 0.017; TLC, P = 0.039) while
anaemia was not associated with increased mortality in
either group (pre-HAART, log-rank = 2.2, P = 0.14;
HAART, Log-rank = 2.1, P = 0.14). Tables 3 and 4 show the
relative effect of selected variables on mortality and tuber-
culosis incidence rates.
History of easy fatigability (Log-rank = 13.8; P < 0.001)
and prolonged fever (Log-rank = 17.2; P < 0.001) pre-
dicted tuberculosis in the pre-HAART group but not in the
HAART group (Log-rank = 0.06; P = 0.80 for fever and
Log-rank = 2.3, P = 0.13 for easy fatigability). History of
tuberculosis was not associated with increased tuberculo-
sis incidence, neither in the pre-HAART group (Log-rank =
1.7; P = 0.19) nor in the HAART group (Log-rank = 2.1; P
= 0.15).
Kaplan-Meier estimates of survival with and without HAART,  Arba Minch Hospital, 2006 Figure 1
Kaplan-Meier estimates of survival with and without 
HAART, Arba Minch Hospital, 2006. This figure shows 
(i) the higher mortality rate in the untreated group, and (ii) 
the high early mortality in both groups. About 20 weeks after 
starting treatment, the mortality rate stabilized in the treated 
group, but in the untreated cohort there was steady increase 
in mortality. The longer curve of the HAART group shows 
the longer follow-up in the treated group.
HAART 180 155 132 112 91 72 37 11 4
Pre-HAART 185 131 77 38 20 2 0 0 0
Table 2: ART associated side effects, Arba Minch Hospital, 2006
Side effect§ Frequency Per cent Time to first episode (weeks)
Median IQR
Peripheral neuropathy 48 38.7 13.1 5.9–23.6
Skin rash 41 33.1 4.6 3.6–13.0
Anaemia 11 8.9 4.4 4.0–16.6
CNS manifestations 10 8.1 5.7 3.1–12.1
Hepatotoxicity 7 5.6 9.8 4.3–12.6
Lactic acidosis 2 1.6 - -
Abnormal fat accumulation 2 1.6 - -
Gynecomastia 2 1.6 - -
Pancreatitis 1 0.8 - -
§ Gastrointestinal symptoms such as diarrhea, vomiting, nausea, etc were not included because it was difficult to distinguish them from disease 
symptomsAIDS Research and Therapy 2006, 3:10 http://www.aidsrestherapy.com/content/3/1/10
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Discussion
We found that HAART decreased death and tuberculosis
incidence rates in HIV infected Ethiopian patients. Mortal-
ity declined by 65% and tuberculosis incidence rate was
reduced by almost 90%. Most of the deaths in the HAART
cohort occurred within the first three months of therapy.
Few patients experienced life-threatening drug side effects.
We did the study under routine care conditions in a typi-
cal Ethiopian district hospital. We were able to follow the
patients and believe the results may be relevant to other
resource-limited settings. The use of community agents in
following up the patients was not only useful to secure
complete data for the research, but proved to be helpful in
the routine clinical work.
However, both the mortality and the tuberculosis inci-
dence rates are higher in this cohort than in cohorts from
the developed world and there is a need to improve the
treatment routines. Particular attention should be on the
early weeks of treatment when mortality is high. Unfortu-
nately, many of our patients had advanced disease at time
of diagnosis. Thus, to reduce mortality, HIV patients may
need to be diagnosed earlier. Treatment programmes need
to work closely with voluntary testing programmes, the
tuberculosis control units and with the HIV prevention
efforts.
Both patients and health workers should be aware that
tuberculosis might occur among patients receiving
HAART. Patients experiencing prolonged fever before
treatment are at higher risk of being diagnosed with tuber-
culosis.
Our results are consistent with findings from the devel-
oped world when HAART was introduced. A protease
inhibitor-containing HAART reduced mortality by 64% in
an Italian cohort [8]. Similarly, a multicenter HAART trial
reported a 62% decrease in mortality among patients with
advanced HIV [9]. To our knowledge, no study has com-
pared HAART with no treatment in an African setting. A
study using virologic and immunological end points
found that HAART was equally effective in African
patients [5] and challenged an earlier report that virologi-
cal failure was more common in Africans [10].
Kaplan Meier estimates of tuberculosis-free survival in the  two cohorts, Arba Minch Hospital, 2006 Figure 3
Kaplan Meier estimates of tuberculosis-free survival 
in the two cohorts, Arba Minch Hospital, 2006. This 
figure shows the high tuberculosis occurrence in the 
untreated group. Unlike the mortality rate which was highest 
in the early weeks, tuberculosis started at about 20 weeks 
after enrolment (pre-HAART) or after starting treatment 
(HAART). This could be because patients might have died 
even before being diagnosed. Additionally, it could be due to 
the time needed to diagnose new cases.
HAART 180 155 132 112 91 72 37 11 4
Pre-HAART 185 131 77 38 20 2 0 0 0
Survival curve according to adjusted Cox regression analysis  shown in Table 3 Figure 2
Survival curve according to adjusted Cox regression analysis 
shown in Table 3.
HAART 180 155 132 112 91 72
Pre-HAART 185 131 77 38 20 2AIDS Research and Therapy 2006, 3:10 http://www.aidsrestherapy.com/content/3/1/10
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While improved survival is encouraging news, it is lower
than in the developed world. A population based study
from Ethiopia showed that adult mortality rate is 11.1 per
1000 PYO [11]. A background of high disease burden and
advanced disease stage could explain the high mortality
rate of 15.4 per 100 PYO among our patients. Since most
of the deaths occurred within the first 12 weeks of treat-
ment, factors associated with advanced disease or the
immune reconstitution syndrome could be possible con-
tributing causes [12]. Though we did not make any
attempt to ascertain the specific causes death, we suspect
undiagnosed tuberculosis either alone or as part of the
immune constitution syndrome to be the cause for some
of the early deaths. This could be particularly true for the
majority of deaths that occurred at home. This highlights
the need for improving the quality of patient manage-
ment during the early phase of treatment, as has been
shown in developed countries [2,13]. A more recent study
confirmed the high early mortality in resource-poor set-
tings and emphasized the need for timely diagnosis and
treatment [14].
Doing studies in resource-limited settings as in Arba
Minch is difficult and adds some limits on how the study
was carried out. Because of limited funds, we were not
able to do CD4 tests. Even if this essential test was not
done, the treatment results were good and the incomplete
laboratory set-up should not be used to deny HAART to
patients in developing countries. The diagnosis of tuber-
culosis was based on clinical, radiological or sputum
examination only. As we were not able to do tuberculosis
cultures, we may have overestimated the number of tuber-
culosis cases diagnosed. As HAART is a lifelong treatment,
we plan to follow the cohort and learn more about the
long-term effects of the drugs and to learn more about
drug adherence.
Recent evidence shows that HAART reduces the risk of
tuberculosis by 70–90% [15-18], as shown in our study.
However, despite the decrease in tuberculosis among
patients treated with HAART, the rate is still high when
compared to HIV-negative patients. In South Africa, the
tuberculosis incidence rates in the HAART and in the pre-
HAART cohort were 2.4 and 9.7 per 100 PYO, respectively
[16] and compare well with our corresponding rates of 3.7
and 11.1 per 100 PYO. With a longer treatment period it
is possible to decrease the tuberculosis incidence to about
1 per 100 PYO [19,20]. However, the tuberculosis inci-
dence rates from Africa are still higher than 0.79 per 100
PYO reported from an Italian cohort [18].
These high tuberculosis incidence rates, when coupled
with the improved survival, could lead to increased tuber-
culosis transmission in the community [18,21]. Thus,
tuberculosis preventive strategies need to be strengthened
with the rapid scale-up of HAART. Some of the suggested
strategies include: early introduction of HAART, isoniazid
(INH) prophylaxis and immune boosting mechanisms
[15]. In the resource-limited settings such as in south Ethi-
opia, the INH prophylaxis seems the more possible alter-
native.
Conclusion
HAART improved survival and decreased tuberculosis
incidence to a level similar to that achieved in the devel-
oped countries during the early years of HAART. This rel-
Table 4: Hazard ratios of tuberculosis incidence rate according to Cox-regression analysis, Arba Minch Hospital, 2006
Factor Crude HR (95%CI) P-value Adjusted HR (95%CI) P-value
HAART (Yes vs. No) 0.09 (0.02–0.37) 0.001 0.11 (0.03–0.48) 0.003
Fever (Yes vs. No) 5.66 (1.85–17.3) 0.002 5.28 (1.67–16.66) 0.005
Hgb (<10 g/dl vs. > = 10 g/
dl)
9.24 (1.19–71.5) 0.033 5.77 (0.70–47.7) 0.104
Easy fatigability (Yes vs. 
No)
1.42 (0.47–4.26) 0.530 1.79 (0.58–5.51) 0.306
Table 3: Hazard ratios (HR) of death according to Cox-regression analyses, Arba Minch Hospital, 2006
Factor Crude HR (95%CI) P-value Adjusted HR (95%CI) P-value
HAART (yes vs. no) 0.38 (0.23–0.62) <0.001 0.35 (0.19–0.63) <0.001
Oral thrush (yes vs. no) 2.64 (1.66–4.19) <0.001 1.15 (0.90–2.63) 0.119
Diarrhea (yes vs. no) 1.84 (1.16–2.93) 0.010 1.43 (0.85–2.40) 0.172
TLC <1200 vs. > = 1200/ml 2.22 (1.30–3.79) 0.004 2.48 (1.32–4.66) 0.005
BMI (<18.5 vs. 18.5+kg/m2 2.50 (1.44–4.34) 0.001 1.83 (1.03–3.27) 0.040
Hgb (<10 vs. > = 10 g/dl) 2.26 (1.21–4.25) 0.010 1.15 (0.55–2.40) 0.710
WHO stage (III-IV vs. II) 3.57 (1.12–11.34) 0.030 2.74 (0.62–12.12) 0.184
BMI= body mass index; Hgb=haemoglobin; TLC=total lymphocyte count; WHO=World Health OrganizationAIDS Research and Therapy 2006, 3:10 http://www.aidsrestherapy.com/content/3/1/10
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ative reduction in mortality and tuberculosis is
encouraging news. However, both the mortality and the
tuberculosis incidence rates were higher in this resource-
limited setting. Since most of the deaths occurred during
the early weeks of treatment, attention should be paid to
this part of the follow-up. The high tuberculosis incidence
rate, when combined with the improved survival, may
lead to increased tuberculosis transmission. This high-
lights the need for strengthening tuberculosis prevention
efforts along with the scale-up of treatment programmes.
Methods
Study setting
Arba Minch Hospital, located 500 km south of Addis
Ababa, is a general hospital with basic facilities for HIV
care and treatment. The hospital has been doing HIV
counselling and testing since the early 1990's and since
January 2002, the services include basic tests to deliver
antiretroviral drugs (ARVs) and to treat opportunistic
infections [7]. In August 2003, Arba Minch hospital was
among the first few public hospitals to start HAART in
Ethiopia. The country did not have a policy on the use of
ARVs until July 2002 [22].
As part of the preparation to start HAART in south Ethio-
pia, we registered and followed all consecutive HIV
infected patients who visited the clinic since January
2003. During this pre-HAART period, patients were fol-
lowed and treated for opportunistic infections. Since
August 2003, we treated patients with HAART. Therefore,
we had two cohorts of patients: the pre-HAART and the
HAART cohorts.
The Pre-HAART cohort
All adult treatment-naïve patients (age > = 15 years) with
symptomatic HIV disease (WHO stage II to IV) who had
follow-up in the HIV unit of the hospital between January
2003 and August 2003 were eligible for this analysis. At
baseline, we examined patients and classified them
according to the WHO staging [23]. A complete blood cell
count (CBC) was done after the clinical staging. CD4
counts were not available. Chest X-ray and sputum for
acid-fast bacilli were done when clinically indicated. Iden-
tified opportunistic diseases were treated according to the
standard in the hospital. We repeated clinical examina-
tions and CBCs every 12 weeks and encouraged the
patients to visit the clinic whenever needed. The results of
the pre-HAART follow-up, including patients with stage I
disease, have been reported elsewhere [24].
The HAART cohort
This study included all consecutive adult patients (age > =
15 years) treated with triple antiretroviral drug at Arba
Minch hospital during the period August 2003 to August
2005. Recruitment into the treatment was based on the
Ethiopian and the WHO treatment guidelines [7,25]. So,
all HIV positive patients with WHO stage II-IV were eligi-
ble to be evaluated for treatment. In stage II, we started
treatment if the patients had a total lymphocyte count
(TLC) of less than 1200/mm3. The patient's willingness to
be treated was another condition for inclusion.
At baseline, we recorded socio-demographic, clinical and
laboratory data in a standardized patient record form. Eli-
gible patients were counselled for drug adherence and
their consent was obtained before drugs were prescribed.
Approved antiretroviral drugs
Generic combinations of stavudine (d4T), lamivudine
(3TC), nevirapine (NVP), zidovudine (ZDV) and efa-
virenz (EFV) are approved for use in district hospitals in
Ethiopia [25]. The first-line drug combination of choice
(d4T/3TC/NVP) was prescribed to all patients if there
were no clear contraindications such as liver disease,
intensive phase of antituberculosis treatment or allergy to
any one of the components.
Stavudine was given as 40 mg or 30 mg (depending on
body weight) twice daily; 3TC 150 mg twice daily; and
NVP 200 mg daily for the first two weeks and then twice
daily after that. ZDV was available only in combination
with 3TC and it was given at a dose of 300 mg twice daily.
The dose of EFV was 600 mg daily. EFV was mainly
reserved for patients in the intensive phase of antitubercu-
losis treatment. All drugs were given orally.
Follow-up assessment
Following the baseline assessment, the patients were pro-
vided with more drugs on four-weekly basis. Each month,
we assessed patients for drug side effects, treatment com-
pliance, measured the body weights, and examined for
new symptoms. Particular attention was given to diagno-
sis of tuberculosis. CBC, liver and renal tests were meas-
ured every 12 weeks.
Follow-up at community level
Each month, a community agent visited the patients in
their homes. These community agents had completed sec-
ondary school and had received extra training on HIV/
AIDS. After each visit, they reported the status of each
patient.
End Points
The primary end point in this study was time to death. All
non-accidental deaths were considered HIV-related. The
secondary end point was time to diagnosis of tuberculo-
sis. We defined and classified tuberculosis according to
the national tuberculosis and leprosy control manual of
Ethiopia [26]. Accordingly, we diagnosed smear positive
pulmonary tuberculosis (PTB+) if two or more initial spu-AIDS Research and Therapy 2006, 3:10 http://www.aidsrestherapy.com/content/3/1/10
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tum examinations were positive for AFB, or one sputum
positive for AFB plus radiographic abnormalities consist-
ent with active TB as determined by a physician. Smear
negative pulmonary tuberculosis (PTB-) was diagnosed if
at least three sputum specimens negative for AFB, and
radiologic abnormalities consistent with TB, and no
response to a course of broad-spectrum antibiotics, and
decision by a physician to treat with a full course of antitu-
berculosis chemotherapy. EPTB refers to TB of organs
other than the lungs, and diagnosis was based on strong
clinical suspicion by a physician.
Patients were regarded as lost to follow-up if they did not
attend the hospital within the previous 90 days and the
community agent did not find the patient. We followed
the patients until they died, moved out of the area or were
lost to follow-up. We regarded the community agent to be
the most reliable informant of outcome occurring at com-
munity level. The data clerk at the clinic reported hospital
deaths.
For the HAART period, censoring time was defined as the
earliest date of the following events: (i) if the person was
alive and on treatment at the end of the study, August 9
2005; (ii) if the person was lost to follow up, the date of
the last contact the patient had with the community agent;
(iii) if the patient was transferred to another institution,
the date of transfer; and (iv) if the patient stopped treat-
ment, the last date of drug resupply plus two months.
Patients in the pre-HAART study were followed until they
were lost, transferred, died, put on HAART, or reached last
date of the pre-HAART follow-up (1 April 2004) which-
ever occurred first. We followed pre-HAART patients
about 90 days into the HAART period until we got infor-
mation about all the patients including those still on their
12-weekly appointment. We calculated time-to-event
from the first date of clinic visit for the pre-HAART cohort
and from the date HAART was started for the HAART
cohort. Thus, the pre-HAART patients who joined the
HAART group contributed person-time to both cohorts at
different periods. All those started on HAART were consid-
ered treated irrespective of the outcome to approximate
the intention-to-treat analysis of randomized trials.
Statistical methods
To assess the event-free survival, we used the Kaplan-
Meier method and the Log-rank test was used to test for
the statistical significance. We also used the Cox-regres-
sion method to find out the effect of HAART on mortality
and on tuberculosis incidence rates. We assessed the rela-
tive effect of the WHO clinical stages, oral thrush, diar-
rhoea, body mass index (BMI), anaemia and total
lymphocyte count (TLC) in predicting mortality in both
the pre-HAART and the HAART groups. Anaemia, history
of prolonged fever, history of easy fatigability, history of
tuberculosis, and the WHO clinical stage were also
assessed as possible predictors of tuberculosis.
We used the cut-off value of 18.5 kg/m2 for low BMI [27].
Since we do not have normal value for haemoglobin
(Hgb) in the study area, we used an arbitrary cut off value
of 10 g/dl to define anaemia. The cut off point for the TLC
was 1200 cells/ml because of its clinical significance in
starting HAART [25].
We calculated death rates as deaths per 100 person-years
of observation (PYO) and the tuberculosis incidence rates
as number of tuberculosis cases per 100 PYO. All patients
were considered to be at risk of developing tuberculosis
during follow-up.
We used SPSS for Windows version 13.0 (SPSS Inc, Chi-
cago, USA.) for data analysis. All completed baseline and
follow-up patient data were entered on the same day of
examination or as soon as they were available. Statistical
tests were considered significant if the two-sided P-value
was <0.05.
Ethical Considerations
The study protocol was approved by the Regional Com-
mittee for Medical Research Ethics in Norway and by the
National Ethics Review Committee in Ethiopia. Patients
gave informed consent for participating in the study.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
DJ, AN and BL designed the study. DJ recruited and fol-
lowed the patients. DJ and BL analyzed the data. DJ, BL
and AN drafted the manuscript and approved the final
version.
Acknowledgements
We thank the doctors, nurses, laboratory technicians and community 
agents of Arba Minch hospital who helped with patient recruitment and fol-
low-up. The University of Bergen funded this study.
References
1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten
GA, Aschman DJ, Holmberg SD: Declining Morbidity and Mortal-
ity among Patients with Advanced Human Immunodefi-
ciency Virus Infection.  N Engl J Med 1998, 338(13):853-860.
2. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P,
Rickenbach M, Robins JM, Egger M: Long-term effectiveness of
potent antiretroviral therapy in preventing AIDS and death:
a prospective cohort study.  Lancet 2005, 366(9483):378-384.
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, Monforte A,
Knysz B, Dietrich M, Philips AN, Lundgren JD: Decline in the AIDS
and death rates in the EuroSIDA study: an observational
study.  Lancet 2003, 362(9377):22-29.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
AIDS Research and Therapy 2006, 3:10 http://www.aidsrestherapy.com/content/3/1/10
Page 8 of 8
(page number not for citation purposes)
4. Paul JW, Raymond M, Catherine S, Gideon R, Robert D, Debra H,
Dorothy O, Peter M, Jonathan M, Badara S, Eve L: Assessment of a
pilot antiretroviral therapy programme in Uganda: patients'
response, survival, and drug resistance.  Lancet 2002,
360:34-40.
5. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Dia-
khate N, Touré Kane NC, Laniece I, Ndir A, Vergne L, Ndoye I,
Mboup S, Sow PS, Delporte E: Long-Term Benefits of Highly
Active Antiretroviral Therapy in Senegalese HIV-1-Infected
Adults.  J Acquir Immune Defic Syndr 2005, 38(1):14-17.
6. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George
E, Kenel-Pierre S, Wright PF, Gulick R, Johnson WD, Pape JW, Fit-
zgerald DW: Antiretroviral Therapy in a Thousand Patients
with AIDS in Haiti.  N Engl J Med 2005, 353(22):2325-2334.
7. WHO. Scaling-up antiretroviral therapy in resource-limited
settings. Treatment guideline for a public health approach.
2003. revision.
8. Pezzotti P, Napoli PA, Acciai S, Boros S, Urciuoli R, Lazzeri V:
Increasing survival time after AIDS in Italy: the role of new
combination antiretroviral therapies. Tuscany AIDS Study
Group.  AIDS 1999, 13(2):249-55.
9. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP,
Kumar PN, Mintz L, Wallach FR, Nemo GJ: Highly Active Antiret-
roviral Therapy Decreases Mortality and Morbidity in
Patients with Advanced HIV Disease.  Ann Intern Med 2001,
135(1):17-26.
10. van den Berg J, Hak E, Vervoort S, Hoepelman IM, Boucher CAB, Sch-
uurman R, Schneider MME: Increased risk of early virological
failure in non-European HIV-1-infected patients in a Dutch
cohort on highly active antiretroviral therapy.  HIV Med 2005,
6(5):299-306.
11. Berhane Y, Hogberg U, Byass P, Wall S: Gender, literacy, and sur-
vival among Ethiopian adults, 1987-96.  Bull World Health Organ
2002, 80(9):714-720.
12. Buckingham SJ, Haddow LJ, Shaw PJ, Miller RF: Immune reconsti-
tution inflammatory syndrome in HIV-infected patients with
mycobacterial infections starting highly active anti-retrovi-
ral therapy.  Clin Radiol 2004, 59(6):505-513.
13. David V, Noya G, Mahboobeh S, Sandro G, Greqory DK, Greg ML,
Timothy RS: Effectiveness of Highly Active Antiretroviral
Therapy among Injection Drug Users with Late-Stage
Human Immunodeficiency Virus Infection.  Am J Epidemiol
2005, 161:999-1012.
14. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P,
Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E,
Sterne JA, May M, Egger M: Mortality of HIV-1-infected patients
in the first year of antiretroviral therapy: comparison
between low-income and high-income countries.  Lancet 2006,
367(9513):817-24.
15. Stephen DL, Linda-Gail B, Robin W: How effectively does
HAART restore immune responses to Mycobacterium
tuberculosis? Implications for tuberculosis control.  AIDS
2005, 19:1113-1124.
16. Badri M, Wilson D, Wood R: Effect of highly active antiretrovi-
ral therapy on incidence of tuberculosis in South Africa: a
cohort study.  Lancet 2002, 359(9323):2059-2064.
17. Santoro-Lopes G, De Pinho AMF, Harrison LH, Schechter M:
Reduced risk of tuberculosis among Brazilian patients with
advanced human immunodeficiency virus infection treated
with highly active antiretroviral therapy.  Clin Infect Dis 2002,
34(4):543-546.
18. Girardi E, Antonucci G, Vanacore P, Libanore M, Errante I, Matteelli
A, Ippolito G, Angarano G, Babudieri S, Cancellieri C, Carbonara S,
Chirianni A, Cingolani A, De Gennaro M, Giomi S, Lo Caputo S, Liuzzi
G, Manzillo E, Meneghin G, Pagano G, Pasticci MB, Pellizzer G, Quir-
ino T, Raineri G, Raviglione M, Rizzi M, Russo R, Salassa B, Santoro D,
Savalli E, Giorgio P, Suter F, Traverso A: Impact of combination
antiretroviral therapy on the risk of tuberculosis among per-
sons with HIV infection.  AIDS 2000, 14(13):1985-1991.
19. Lawn SD, Badri M, Wood R: Tuberculosis among HIV-infected
patients receiving HAART: long term incidence and risk fac-
tors in a South African cohort.  AIDS 2005, 19(18):2109-2116.
20. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X: Risk
Factors for Active Tuberculosis after Antiretroviral Treat-
ment Initiation in Abidjan.  Am J Respir Crit Care Med 2005,
172(1):123-127.
21. Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tan-
suphaswaswadikul S, Bowonwatanuwong C: Opportunistic infec-
tions after the initiation of highly active antiretroviral
therapy in advanced AIDS patients in an area with a high
prevalence of tuberculosis.  AIDS 2003, 17:2129-2131.
22. FDRE: Policy on antiretroviral drugs supply and use.  Addis
Ababa 2002.
23. WHO:  Acquired immune deficiency syndrome (AIDS):
interim proposal for a WHO staging system for HIV-1 infec-
tion and disease.  Wkly Epidemiol Rec 1990, 65:221-228.
24. Jerene D, Lindtjørn B: Disease progression among untreated
HIV-infected patients in south Ethiopia: Implications for
patient care.  MedGenMed 2005, 7(3):66.
25. MOH/HAPCO/DACA:  Guidelines for use of antiretroviral
drugs in Ethiopia.  Addis Ababa 2003.
26. The Federal Ministry of Health of Ethiopia: National Tuberculosis
and Leprosy Control Programme Manual.  Addis Ababa 2002.
27. FAO: Body Mass Index – A measure of chronic energy defi-
ciency in adults.  Food and Nutrition Paper 56. Food and Agriculture
Organization 1994.